Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Robert James Glynn, Sc.D., Ph.D.

Co-Author

This page shows the publications co-authored by Robert Glynn and Daniel Solomon.
Connection Strength

4.848
  1. Design of cluster-randomized trials of quality improvement interventions aimed at medical care providers. Med Care. 2007 Oct; 45(10 Supl 2):S38-43.
    View in: PubMed
    Score: 0.364
  2. Causal mediation analysis of the relationship of canakinumab's effect against subsequent gout flares and high-sensitivity C-reactive protein in CANTOS. Arthritis Care Res (Hoboken). 2021 Dec 07.
    View in: PubMed
    Score: 0.243
  3. Effect of Low-Dose Methotrexate on eGFR and Kidney Adverse Events: A Randomized Clinical Trial. J Am Soc Nephrol. 2021 Sep 22.
    View in: PubMed
    Score: 0.240
  4. Adverse effects related to methotrexate polyglutamate levels: adjudicated results from the cardiovascular inflammation reduction trial. Rheumatology (Oxford). 2021 06 18; 60(6):2963-2968.
    View in: PubMed
    Score: 0.236
  5. Adverse Effects of Low-Dose Methotrexate in a Randomized Double-Blind Placebo-Controlled Trial: Adjudicated Hematologic and Skin Cancer Outcomes in the Cardiovascular Inflammation Reduction Trial. ACR Open Rheumatol. 2020 Dec; 2(12):697-704.
    View in: PubMed
    Score: 0.226
  6. Pulmonary Adverse Events in Patients Receiving Low-Dose Methotrexate in the Randomized, Double-Blind, Placebo-Controlled Cardiovascular Inflammation Reduction Trial. Arthritis Rheumatol. 2020 12; 72(12):2065-2071.
    View in: PubMed
    Score: 0.225
  7. Adverse Effects of Low-Dose Methotrexate: A Randomized Trial. Ann Intern Med. 2020 03 17; 172(6):369-380.
    View in: PubMed
    Score: 0.215
  8. A tool for empirical equipoise assessment in multigroup comparative effectiveness research. Pharmacoepidemiol Drug Saf. 2019 07; 28(7):934-941.
    View in: PubMed
    Score: 0.204
  9. Multinomial Extension of Propensity Score Trimming Methods: A Simulation Study. Am J Epidemiol. 2019 03 01; 188(3):609-616.
    View in: PubMed
    Score: 0.201
  10. Relationship of Interleukin-1ß Blockade With Incident Gout and Serum Uric Acid Levels: Exploratory Analysis of a Randomized Controlled Trial. Ann Intern Med. 2018 10 16; 169(8):535-542.
    View in: PubMed
    Score: 0.195
  11. Effects of analgesics on bone mineral density: A longitudinal analysis of the prospective SWAN cohort with three-group matching weights. Pharmacoepidemiol Drug Saf. 2018 02; 27(2):182-190.
    View in: PubMed
    Score: 0.185
  12. Effects of xanthine oxidase inhibitors on cardiovascular disease in patients with gout: a cohort study. Am J Med. 2015 Jun; 128(6):653.e7-653.e16.
    View in: PubMed
    Score: 0.152
  13. Dipeptidyl peptidase-4 inhibitors in type 2 diabetes may reduce the risk of autoimmune diseases: a population-based cohort study. Ann Rheum Dis. 2015 Nov; 74(11):1968-75.
    View in: PubMed
    Score: 0.145
  14. Risk of high-grade cervical dysplasia and cervical cancer in women with systemic inflammatory diseases: a population-based cohort study. Ann Rheum Dis. 2015 Jul; 74(7):1360-7.
    View in: PubMed
    Score: 0.142
  15. The comparative safety of analgesics in older adults with arthritis. Arch Intern Med. 2010 Dec 13; 170(22):1968-76.
    View in: PubMed
    Score: 0.114
  16. The comparative safety of opioids for nonmalignant pain in older adults. Arch Intern Med. 2010 Dec 13; 170(22):1979-86.
    View in: PubMed
    Score: 0.114
  17. NSAID switching and short-term gastrointestinal outcome rates after the withdrawal of rofecoxib. Pharmacoepidemiol Drug Saf. 2009 Dec; 18(12):1134-42.
    View in: PubMed
    Score: 0.106
  18. Subgroup analyses to determine cardiovascular risk associated with nonsteroidal antiinflammatory drugs and coxibs in specific patient groups. Arthritis Rheum. 2008 Aug 15; 59(8):1097-104.
    View in: PubMed
    Score: 0.097
  19. Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk. Arthritis Rheum. 2006 May; 54(5):1378-89.
    View in: PubMed
    Score: 0.083
  20. Adjusting for unmeasured confounders in pharmacoepidemiologic claims data using external information: the example of COX2 inhibitors and myocardial infarction. Epidemiology. 2005 Jan; 16(1):17-24.
    View in: PubMed
    Score: 0.075
  21. A Medicare database review found that physician preferences increasingly outweighed patient characteristics as determinants of first-time prescriptions for COX-2 inhibitors. J Clin Epidemiol. 2005 Jan; 58(1):98-102.
    View in: PubMed
    Score: 0.075
  22. Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records. Am Heart J. 2004 Jul; 148(1):99-104.
    View in: PubMed
    Score: 0.073
  23. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation. 2004 May 04; 109(17):2068-73.
    View in: PubMed
    Score: 0.072
  24. Determinants of selective cyclooxygenase-2 inhibitor prescribing: are patient or physician characteristics more important? Am J Med. 2003 Dec 15; 115(9):715-20.
    View in: PubMed
    Score: 0.070
  25. The hidden cost of nonselective nonsteroidal antiinflammatory drugs in older patients. J Rheumatol. 2003 Apr; 30(4):792-8.
    View in: PubMed
    Score: 0.067
  26. Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet. 2002 Jul 06; 360(9326):90.
    View in: PubMed
    Score: 0.063
  27. Nonsteroidal anti-inflammatory drug use and acute myocardial infarction. Arch Intern Med. 2002 May 27; 162(10):1099-104.
    View in: PubMed
    Score: 0.063
  28. Which patients with unstable angina or non-Q-wave myocardial infarction should have immediate cardiac catheterization? A clinical decision rule for predicting who will fail medical therapy. J Clin Epidemiol. 2002 Feb; 55(2):121-8.
    View in: PubMed
    Score: 0.062
  29. Exploring patient experiences coping with using multiple medications: a qualitative interview study. BMJ Open. 2021 11 22; 11(11):e046860.
    View in: PubMed
    Score: 0.061
  30. Risk of venous thromboembolism associated with methotrexate versus hydroxychloroquine for rheumatoid arthritis: A propensity score-matched cohort study. Semin Arthritis Rheum. 2021 12; 51(6):1242-1250.
    View in: PubMed
    Score: 0.060
  31. Use of risk stratification to identify patients with unstable angina likeliest to benefit from an invasive versus conservative management strategy. J Am Coll Cardiol. 2001 Oct; 38(4):969-76.
    View in: PubMed
    Score: 0.060
  32. Academic detailing to improve use of broad-spectrum antibiotics at an academic medical center. Arch Intern Med. 2001 Aug 13-27; 161(15):1897-902.
    View in: PubMed
    Score: 0.059
  33. Testing the Effects of Disease-Modifying Antirheumatic Drugs on Vascular Inflammation in Rheumatoid Arthritis: Rationale and Design of the TARGET Trial. ACR Open Rheumatol. 2021 Jun; 3(6):371-380.
    View in: PubMed
    Score: 0.058
  34. Low-Dose Methotrexate for the Prevention of Atherosclerotic Events. N Engl J Med. 2019 02 21; 380(8):752-762.
    View in: PubMed
    Score: 0.049
  35. Matching Weights to Simultaneously Compare Three Treatment Groups: Comparison to Three-way Matching. Epidemiology. 2017 05; 28(3):387-395.
    View in: PubMed
    Score: 0.044
  36. Statin therapy and risk of fracture: results from the JUPITER randomized clinical trial. JAMA Intern Med. 2015 Feb; 175(2):171-7.
    View in: PubMed
    Score: 0.038
  37. Risk of venous thromboembolism in patients with rheumatoid arthritis: initiating disease-modifying antirheumatic drugs. Am J Med. 2015 May; 128(5):539.e7-17.
    View in: PubMed
    Score: 0.038
  38. Rationale and design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis. Am Heart J. 2013 Aug; 166(2):199-207.e15.
    View in: PubMed
    Score: 0.034
  39. Matching by propensity score in cohort studies with three treatment groups. Epidemiology. 2013 May; 24(3):401-9.
    View in: PubMed
    Score: 0.034
  40. Supplementing claims data with outpatient laboratory test results to improve confounding adjustment in effectiveness studies of lipid-lowering treatments. BMC Med Res Methodol. 2012 Nov 26; 12:180.
    View in: PubMed
    Score: 0.033
  41. Simultaneously assessing intended and unintended treatment effects of multiple treatment options: a pragmatic "matrix design". Pharmacoepidemiol Drug Saf. 2011 Jul; 20(7):675-83.
    View in: PubMed
    Score: 0.029
  42. The association between statin use and outcomes potentially attributable to an unhealthy lifestyle in older adults. Value Health. 2011 Jun; 14(4):513-20.
    View in: PubMed
    Score: 0.029
  43. Effect of rosuvastatin on hemoglobin levels in patients with anemia and low-grade inflammation: a post hoc analysis of the JUPITER trial. J Clin Pharmacol. 2011 Oct; 51(10):1483-7.
    View in: PubMed
    Score: 0.029
  44. Rationale and design of the Study Assessing the Effect of Cardiovascular Medications Provided as Low-cost, Evidence-based Generic Samples (SAMPLES) trial. Am Heart J. 2009 Apr; 157(4):613-9.
    View in: PubMed
    Score: 0.025
  45. Agreement of diagnosis and its date for hematologic malignancies and solid tumors between medicare claims and cancer registry data. Cancer Causes Control. 2007 Jun; 18(5):561-9.
    View in: PubMed
    Score: 0.022
  46. Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. Arthritis Rheum. 2006 Sep; 54(9):2757-64.
    View in: PubMed
    Score: 0.021
  47. Explained variation in a model of therapeutic decision making is partitioned across patient, physician, and clinic factors. J Clin Epidemiol. 2006 Jan; 59(1):18-25.
    View in: PubMed
    Score: 0.020
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.